Research & Development: Page 77
-
PharmaVoice Team/PharmaVoice
What's New
Ventiv Health Inc., MDS Pharma Services,and Paul Capital Partners have joined forces to provide lifesci ences companies with a broad range of development, commercialization,and investment support. The alliance combines the drug discovery and development expertise of MDS Pharma Services,the commer...
By PharmaVoice Team • March 11, 2009 -
PharmaVoice Team/PharmaVoice
Defining GLOBAL
BY DENISE MYSHKO AND ROBIN ROBINSON KARLA ANDERSON Managing Director, Life Sciences BearingPoint Global is a perspective of looking at the business in its totality, not just at a given market or a given country or a given set of rules and regulations, but at the business as a whole. It’s always c...
By Denise Myshko and Robin Robinson • March 1, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Global Thought leaders
Karla Anderson, Managing Director, Life Sciences, BearingPoint Inc. — A provider of management and technology consulting services. For more information, visit bearingpoint.com. Leone Atkinson, M.D., Senior Director of Clinical Development, PTC Therapeutics Inc. — A biopharmaceutical company focus...
By PharmaVoice Team • Feb. 27, 2009 -
PharmaVoice Team/PharmaVoice
An Approach to Language in GLOBAL Trials
Informed consent procedure requires that written consent be translated into the patient’s native language, and any unique cultural aspects be taken into account. In addition, many countries have multiple language translation requirements, depending on the population demographics. When linguistic ...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
GLOBAL Patient Recruitment
BY DENISE MYSHKO Patient recruitment has and will continue to evolve in a global marketplace, with all countries competing equally and being measured on performance for the quality of patients screened and recruited within the shortest amount of time. “The U.S. market was the most developed in te...
By Denise Myshko • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
GLOBAL Talent
As companies globalize and seek to maximize the opportunities and challenges that result, they need to ensure that they have an understanding of the talent potential that exists globally. All too often companies think in local operating terms or seek to attract talent within the country where the...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Deirdre CONNELLY GlaxoSmithKline Selects Head of North American Pharma Business Deirdre Connelly, former president of U.S. operations at Eli Lilly, has joined GlaxoSmithKline (GSK) as president, North American pharmaceuticals. Ms. Connelly was appointed president of U.S. opera...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
E-media
New electronic and web-based applications, sites, and technologies Ziment Unveils New Market Research Tool Ziment has introduced an analytic technique, SequenceZ, which allows forecasters to make better use of market research by providing more accurate assessments of the effect of product launch ...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies GfK Consolidates Market Research Operations Operating as one entity allows GfK Healthcare to pull together its strengths and individual leadership positions across multi-client research. The GfK U.S. Healthcare Companies has consolidated it...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D Trends affectinga the healthcare industry EU Candidate Countries Offer Ripe Field for Clinical-Trial Recruitment Conducting clinical trials in Europe is not a new concept for global pharmaceutical companies, but choosing the country in which to hold a particular tria...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
Upfront
Milestones kinetix turns 10 Kinetix, a specialized healthcare consulting firm that uses exclusive, proprietary communication channels to build and implement live and online marketing programs, is celebrating its 10th anniversary. Over the last 10 years, Kinetix has developed strategies to communi...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
Dr. Donald G. Payan — Reaching for the Stars Through Molecules
As cofounder, executive VP, and chief scientific officer of Rigel Pharmaceuticals, Dr. Donald G. Payan intends to have his company become the brightest star among those hunting for new drugs. LIFE’S BIGGEST DECISIONS OFTEN CAN BE ATTRIBUTED TO COINCIDENCE. In the mid-1960s, Dr. Payan arrived in C...
By Taren Grom • Feb. 23, 2009 -
PharmaVoice Team/PharmaVoice
Addressing Pharma's $40 Billion Challenge
Addressing Pharma’s $40 Billion Challenge With A MAJOR GAP IN ITS PIPELINE of potential replacement blockbusters, the pharmaceutical industry is FACING A CRISIS. IN AN EXCLUSIVE TO PHARMAVOICE, MICHAEL PERRY, PH.D., PRESIDENT AND CEO OF PHARSIGHT CORP., AND ARTHUR REIDEL, CHAIRMAN OF THE BOARD OF...
By PharmaVoice Team • Feb. 23, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEB-BASED APPLICATIONS, SITES, AND TECHNOLOGIES PatientLinx.com Offers NEWS UPDATES BY DISEASE AND THERAPEUTIC CATEGORIES MDLinx has launched PatientLinx.com, a free Website that provides reliable clinical updates for patients. PatientLinx aggregates research by disease and the...
By PharmaVoice Team • Feb. 23, 2009 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTHCARE-RELATED PRODUCTS, SERVICES, AND COMPANIES NOP World Health Forms a New Division to RESPOND TO PHARMACEUTICAL PUBLIC-RELATIONS CRISES Through a combination of in-depth therapeutic class analyses, events-driven Web research, and multi-stake holder image tracking and reputation assess...
By PharmaVoice Team • Feb. 22, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
SALES, MARKETING, AND R&D TRENDS AFFECTING THE HEALTHCARE INDUSTRY GENERICS SECTOR Expected to Double by 2007 According to Datamonitor, by 2007 the generics market is expected to be valued at $57 billion, more than twice its estimated value of $27 billion in 2001. Researchers at the company c...
By PharmaVoice Team • Feb. 22, 2009 -
PharmaVoice Team/PharmaVoice
Raise Your Voice: Letters
LETTERS Two critical areas of success Missed Opportunities Your article on “The Patient Pipeline” highlighted many of the difficulties in patient accrual and retention. Unfortunately the solutions in my opinion missed two critical success factors. As CEO and cofounder of MCSI, the largest U.S.-b...
By PharmaVoice Team • Feb. 22, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Funding in a closed space The healthcare private equity market was down in 2002, and industry experts don’t expect a gr eat deal of improvement in 2003. Venture capital firms are sit ting on massive funds and are still doing deals, but according to Russell LaMontagne, president and founder of Cor...
By Taren Grom • Feb. 22, 2009 -
PharmaVoice Team/PharmaVoice
Joe Krivulka: A Reliable Guy
Joe Krivulka Small opportunities are turning into big business for Joe Krivulka and Reliant Pharmaceuticals LLC, the company he cofounded just two years ago. Mr. Krivulka is seizing the opportunity to breathe new life into products being cast off by the pharmaceutical giants. “Big pharma has prod...
By Kim Ribbink • Feb. 21, 2009 -
PharmaVoice Team/PharmaVoice
A Therapeutic Path to Success
The marketers of Cox2 antiinflammatory drugs, have enjoyed two years of recordbreaking sales, but with new products poised to come to market, the challenge will be to hold onto their strong positions. Cox2 inhibitors entered the market with a splash with the launch of Celebrex in 1998. The Pharma...
By Virginia Kirk • Feb. 21, 2009 -
PharmaVoice Team/PharmaVoice
The Toll of Terror
was never going to be a stellar year for global economies, but until September 11, 2001, many in the business world predicted a quick recovery. Those hopes have faded somewhat as consumer spending, rising unemployment, and business uncertain ty plague some sectors. The biopharmaceuti cal industry...
By PharmaVoice Team • Feb. 21, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES Free drug samples handed out to patients in a physician’s office soon may be replaced with printed vouchers that physicians retrieve online for patients to redeem at a pharmacy free of charge. MedManage Systems Inc., an innovator i...
By PharmaVoice Team • Feb. 17, 2009 -
PharmaVoice Team/PharmaVoice
What's New
In a move to solidify its commitment to multicul tural and multiethnic communities, Torre Lazur McCann HealthCare Worldwide has created a new Multicultural Healthcare Marketing Business unit to focus on specific needs and values.The standalone group,a part of theTorre Lazur McCann corridor,pro vi...
By PharmaVoice Team • Feb. 17, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Aging female population presents NEW CHALLENGES in HRT MARKET The growing number of postmenopausal women translates into new challenges for clinicians and is leading to increased focus on the hormone replacement therapy market. Hormone Replacement Therapy, a study from Decision Resources Inc., id...
By PharmaVoice Team • Feb. 17, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
America’s pharmaceutical industry is helping the process of healing the nation in the wake of September 11th. Within hours of the terrorist attacks on New York and Washington, America’s pharmaceutical companies responded with medicines and vaccines, supplies for workers and rescuers, and aid for ...
By Taren Grom • Feb. 17, 2009
Previous
